Comparison of Efficacy and Ocular Surface Disease Assessment Between BRIDIN- PLUS® Eye Drops and COMBIGAN® Eye Drops in Glaucoma or Ocular Hypertensive Patients

Comparison of Efficacy and Ocular Surface Disease Assessment between BRIDIN-plus Eye drops and Combigan Eye drops in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized, Multi-center Trial

Start Date08 Oct 2021

Sponsor / Collaborator

CHA University

[+1]

TCTR20241005001

/ CompletedPhase 3IIT

The difference of IOP post intra vitreous injection among preoperative COSOPT, Combigan and Simbrinza instillation

Start Date01 Dec 2020

Sponsor / Collaborator-

NCT02623023

/ WithdrawnNot ApplicableIIT

Brimonidine/Timolol Fixed Combination Prophylaxis for Intraocular Pressure Elevation Following Intravitreal Injection of Antivascular Endothelial Growth Factor

The purpose of our study is to determine the effect of prophylactic treatment with brimonidine/timolol fixed combination (Combigan®, Allergan; Dublin, IRL) or placebo therapy (Refresh tears®, Allergan; Dublin, IRL) on long-term IOP measurements in patients receiving serial intravitreal injection of 0.5 mg ranibizumab (0.05 mL) with six months follow-up. Intraocular pressure measurements will be correlated with changes on ancillary testing (Humphrey 24-2 visual field testing and optical coherence tomography (OCT) of the optic nerve head (ONH). Our study would be the first large, prospective, randomized double-blind placebo-controlled trial to examine the relationship between anti-vascular endothelial growth factor (VEGF) therapy and sustained ocular hypertension.

Start Date01 Jan 2019

Sponsor / Collaborator

McMaster University

100 Clinical Results associated with Brimonidine Tartrate/Timolol Maleate

100 Translational Medicine associated with Brimonidine Tartrate/Timolol Maleate

100 Patents (Medical) associated with Brimonidine Tartrate/Timolol Maleate

Literatures (Medical) associated with Brimonidine Tartrate/Timolol Maleate

01 Sep 2023·Advances in therapy

Randomized Multicenter Clinical Trial Comparing 0.1% Brimonidine/0.5% Timolol Versus 1% Dorzolamide/0.5% Timolol as Adjuncts to Prostaglandin Analogues: Aibeta Crossover Study.

Article

Author: Yamashita, Takehiro ; Mori, Sotaro ; Ozaki, Mineo ; Ishida, Akiko ; Tsutsui, Aika ; Yoshida, Akiko ; Inoue, Kenji ; Sagara, Takeshi ; Shiokawa, Minako ; Watanabe-Kitamura, Fumika ; Inatani, Masaru ; Inoue, Toshihiro ; Hayashi, Ken ; Nakamura, Makoto ; Lee, Jinhee ; Urahashi, Mai ; Kano, Kiyoshi ; Kagaya, Fumie ; Tanabe, Hirotaka ; Kanamori, Akiyasu ; Tanito, Masaki ; Yamada-Nakanishi, Yuko ; Kuwamura, Rika ; Kido, Noriaki ; Manabe, Kaoru ; Otani, Shinichiro ; Abe, Hideki ; Matsuyama, Akiko ; Kuwayama, Yasuaki ; Inoue, Chizuru ; Saito, Yoshiaki ; Murai, Yusuke ; Sakono, Takato ; Oi, Junko ; Arimura, Shogo ; Nakakura, Shunsuke ; Aoki, Ryota ; Sakono, Takuto ; Nakagawa, Satoko ; Ishiyama, Sosuke ; Suzuki, Katsuyoshi ; Iwasaki, Kentaro ; Musashi, Kunihiro ; Sunagawa, Hiromi ; Kurimoto, Takuji ; Orii, Yusuke ; Sameshima, Motoyasu ; Manabe, Shinichi ; Takaki, Keiko ; Ueda, Kaori

INTRODUCTIONThis multicenter, randomized, comparative, and investigator-masked crossover clinical trial sought to compare the efficacy and tolerability of fixed combinations of 0.1% brimonidine/0.5% timolol (BTFC) versus 1% dorzolamide/0.5% timolol (DTFC) as adjunctive therapies to prostaglandin analogues.METHODSA total of 110 patients with open-angle glaucoma or ocular hypertension previously treated with prostaglandin analogue monotherapy were randomized to receive either BTFC or DTFC as adjunctive therapy for 8 weeks. These patients were then crossed over to the alternative treatment arm for another 8 weeks. The reduction in intraocular pressure (IOP) (primary outcome), occurrence of adverse events, ocular discomfort after instillation, and patient preference (secondary outcomes) were recorded through patient interviews.RESULTSBTFC instillation for 8 weeks reduced IOP by 3.55 mmHg, demonstrating non-inferiority to DTFC instillation (3.60 mmHg; P < 0.0001, mixed-effects model). Although adverse events were rare with both combinations, patients reported greater discomfort with DTFC than with BTFC (P < 0.0001). More patients preferred BTFC (P < 0.0001) over DTFC, as BTFC caused minimal or no eye irritation.CONCLUSIONAs BTFC offered better tolerability than DTFC with comparable reduction in IOP, we recommend it as an alternative for patients who experience ocular discomfort with DTFC-prostaglandin analogue combination therapy.TRIAL REGISTRATION NUMBERjRCTs051190125.

01 Sep 2020·American Journal of Ophthalmology Case Reports

A case of the blues: Inadvertent ocular injury from accidental instillation of blue ink

Author: Port, Alexander D ; Brissette, Ashley R ; Sippel, Kimberly C

PURPOSEMany consumer products and non-ophthalmic medications are packaged in plastic "eye dropper" bottles, posing a risk of accidental ocular chemical injury when these substances are mistaken for eye drops.OBSERVATIONSWe present the case of an elderly glaucoma patient who mistook blue stamper ink for the glaucoma medication Combigan®, and suffered ocular injury as a result.CONCLUSIONS AND IMPORTANCEThe packaging of non-ophthalmic products in plastic "eye dropper" bottles poses a significant risk of accidental ocular chemical injury. Elderly individuals with low vision and/or cognitive deficits may be at particular risk of accidental injury. Ophthalmologists have been calling for a greater distinction between the packaging of ophthalmic and non-ophthalmic products for over 35 years, but to date little progress has been made in this regard.

01 Jul 2016·Pediatric Dermatology

Brimonidine Toxicity Secondary to Topical Use for an Ulcerated Hemangioma

Author: Gill, Kamalvir ; Raimer, Patricia ; Golden, Alex ; Bayart, Cheryl ; Desai, Ritu ; Tamburro, Joan

AbstractCombigan (Allergan, Irvine, CA) is an ophthalmic solution that combines 0.2% brimonidine, a selective α‐2 adrenergic agonist, with 0.5% timolol, a nonselective β‐adrenergic antagonist. It is approved for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. There have been recent reports of successful treatment of superficial infantile hemangiomas (IHs) using Combigan topically. We report the case of a 2‐month‐old girl who developed life‐threatening brimonidine toxicity requiring intubation and mechanical ventilation secondary to central nervous system depression and apnea after topical application to an ulcerated IH.

News (Medical) associated with Brimonidine Tartrate/Timolol Maleate

13 Apr 2023

·www.biospace.com

UPSHER-SMITH EXPANDS OPHTHALMIC PORTFOLIO WITH LAUNCH OF BRIMONIDINE TARTRATE AND TIMOLOL MALEATE OPHTHALMIC SOLUTION

MAPLE GROVE, Minn., April 13, 2023 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced it has expanded its ophthalmic portfolio with the launch of Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%/0.5%, an AB-rated generic equivalent to the branded product Combigan®.* This product launch is a result of Upsher-Smith's strategic partnership with RAFARM UK that includes the development and distribution of six ophthalmic and otic ANDA products. The brimonidine tartrate and timolol maleate ophthalmic solution market had U.S. sales of approximately $392 million for the 12 months ending February 2023 according to IQVIA. Product Information For questions about ordering, please call Upsher-Smith at 1-800-654-2299. Please refer to full Prescribing Information for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution here. You can also call 1-888-650-3789 to obtain a copy of the full Prescribing Information. You are encouraged to report suspected adverse reactions to Upsher-Smith Laboratories, LLC at 1-855-899-9180 or to the FDA by visiting . About Upsher-Smith Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. The company brings brands and generics to a wide array of customers, always backed by its attentive level of service, strong industry relationships, and dedication to uninterrupted supply. For more information, visit . About RAFARM RAFARM is an innovation-driven, dynamically growing pharmaceutical company and a well-established European manufacturer with an outward-looking orientation that invests 13% of net turnover in Research and Development. At RAFARM, we expand our exports worldwide and we open new markets. We constantly enhance our expertise in complex pharmaceutical products and invest in high-tech platforms for the development and production of ophthalmics and injectables. We introduce high technology in our state-of-the-art sterile manufacturing plant and create new production lines with cutting-edge technology and robotic equipment. At RAFARM, we evolve beyond the obvious and make a positive impact on people's lives. LinkedIn: *Combigan is a registered trademark of Allergan, Inc.

27 Sep 2022

·www.prnewswire.com

Open-Angle Glaucoma Therapeutics Market to Record a CAGR of 7.18%, Development of Biologics to be a Key Trend - Technavio

NEW YORK, Sept. 27, 2022 /PRNewswire/ -- One of the key trends in the open-angle glaucoma therapeutics market is the development of biologics. The market landscape largely contains small molecules, including PGAs and non-PGAs. These molecules are the main option for the treatment of open-angle glaucoma. However, side effects such as lack of patient adherence and the high cost of drugs have resulted in unmet medical needs for effective novel treatments. Several biologics offer better safety and efficacy over small molecules. Thus, the development of new biologics is expected to address the unmet needs for safe and novel treatment of open-angle glaucoma. This, in turn, will boost the growth of the market during the forecast period. Continue Reading Technavio has announced its latest market research report titled Global Open-Angle Glaucoma Therapeutics Market 2022-2026 The open-angle glaucoma therapeutics market size is expected to grow by USD 2.58 billion from 2021 to 2026. In addition, the growth momentum of the market will accelerate at a CAGR of 7.18% during the forecast period, according to Technavio. The promising pipeline and recent approvals are driving the open-angle glaucoma therapeutics market growth. However, factors such as advances in glaucoma surgeries may challenge the market growth. Get a comprehensive report summary that describes the market size and forecast along with research methodology. The FREE sample report is available in PDF format Open-Angle Glaucoma Therapeutics Market: Product Landscape By product, the market has been segmented into PGAs and non-PGAs. The PGAs segment will be the largest contributor to market growth during the forecast period. PGAs are the first-line treatment for open-angle glaucoma. Currently, Bimatoprost, latanoprost, and travoprost are the available PGAs in the market, which are approved for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Such factors will boost the market growth during the forecasted period. Open-Angle Glaucoma Therapeutics Market: Geographic Landscape By geography, the market has been segmented into North America, Europe, APAC, and Rest of World (ROW). North America is going to have lucrative growth during the forecast period. About 51% of the market's overall growth is expected to originate from the region. The US and Canada are the key countries in the open-angle glaucoma therapeutics market in North America. Open-Angle Glaucoma Therapeutics Market: Key Companies and their Offerings AbbVie Inc., Aerie Pharmaceuticals Inc, Alcon Inc., Bausch Health Co Inc, D.Western, Therapeutics Institute Inc, Hikma Pharmaceuticals Plc, Laboratories Sophia, Merck and Co. Inc., Nicox SA, Novartis AG, Ocuphire Pharma Inc, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., PharmaMar SA, Santen Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd, Taro Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., among others, are the main players in the market. The key offerings of some of these vendors are listed below: AbbVie Inc. - The company offers open-angle glaucoma therapeutics such as Lumigan and Combigan. Aerie Pharmaceuticals Inc - The company offers open-angle glaucoma therapeutics, namely Rocklatan and Rhopressa. Alcon Inc. - The company offers open-angle glaucoma therapeutics, namely Travatan. Bausch Health Co Inc - The company offers open-angle glaucoma therapeutics, namely Vyzulta. Hikma Pharmaceuticals Plc - The company offers open-angle glaucoma therapeutics, namely Diazepam. This report provides a full list of key vendors, their strategies, and the latest developments. Request a FREE PDF Sample Now Open-Angle Glaucoma Therapeutics Market: What Our Reports Offer Market share assessments for the regional and country-level segments Strategic recommendations for the new entrants Covers market data for 2021, 2022, until 2026 Market trends (drivers, opportunities, threats, challenges, investment opportunities, and recommendations) Strategic recommendations in key business segments based on the market estimations Competitive landscaping mapping the key common trends Company profiling with detailed strategies, financials, and recent developments Supply chain trends mapping the latest technological advancements Related Reports Myopia and Presbyopia Treatment Market by Type and Geography - Forecast and Analysis 2022-2026: The myopia and presbyopia treatment market share is expected to increase by USD 7.22 billion from 2021 to 2026. Ophthalmology Therapeutics Market by Product and Geography - Forecast and Analysis 2021-2025: The ophthalmology therapeutics market size has the potential to grow by USD 12.34 billion during 2020-2025 Browse Health Care Market Reports Table of Contents 1 Executive Summary 1.1 Market overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Product Exhibit 06: Executive Summary – Chart on Incremental Growth Exhibit 07: Executive Summary – Data Table on Incremental Growth Exhibit 08: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 09: Parent market Exhibit 10: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 11: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 12: Market segments 3.3 Market size 2021 3.4 Market outlook: Forecast for 2021-2026 Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million) Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million) Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%) Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%) 4 Five Forces Analysis 4.1 Five forces summary Exhibit 17: Five forces analysis - Comparison between 2021 and 2026 4.2 Bargaining power of buyers Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026 4.3 Bargaining power of suppliers Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026 4.4 Threat of new entrants Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026 4.5 Threat of substitutes Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026 4.6 Threat of rivalry Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026 4.7 Market condition Exhibit 23: Chart on Market condition - Five forces 2021 and 2026 5 Market Segmentation by Product 5.1 Market segments Exhibit 24: Chart on Product - Market share 2021-2026 (%) Exhibit 25: Data Table on Product - Market share 2021-2026 (%) 5.2 Comparison by Product Exhibit 26: Chart on Comparison by Product Exhibit 27: Data Table on Comparison by Product 5.3 PGAs - Market size and forecast 2021-2026 Exhibit 28: Chart on PGAs - Market size and forecast 2021-2026 ($ million) Exhibit 29: Data Table on PGAs - Market size and forecast 2021-2026 ($ million) Exhibit 30: Chart on PGAs - Year-over-year growth 2021-2026 (%) Exhibit 31: Data Table on PGAs - Year-over-year growth 2021-2026 (%) 5.4 Non-PGAs - Market size and forecast 2021-2026 Exhibit 32: Chart on Non-PGAs - Market size and forecast 2021-2026 ($ million) Exhibit 33: Data Table on Non-PGAs - Market size and forecast 2021-2026 ($ million) Exhibit 34: Chart on Non-PGAs - Year-over-year growth 2021-2026 (%) Exhibit 35: Data Table on Non-PGAs - Year-over-year growth 2021-2026 (%) 5.5 Market opportunity by Product Exhibit 36: Market opportunity by Product ($ million) 6 Customer Landscape 6.1 Customer landscape overview Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 7 Geographic Landscape 7.1 Geographic segmentation Exhibit 38: Chart on Market share by geography 2021-2026 (%) Exhibit 39: Data Table on Market share by geography 2021-2026 (%) 7.2 Geographic comparison Exhibit 40: Chart on Geographic comparison Exhibit 41: Data Table on Geographic comparison 7.3 North America - Market size and forecast 2021-2026 Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million) Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million) Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%) Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%) 7.4 Europe - Market size and forecast 2021-2026 Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%) Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%) 7.5 APAC - Market size and forecast 2021-2026 Exhibit 50: Chart on APAC - Market size and forecast 2021-2026 ($ million) Exhibit 51: Data Table on APAC - Market size and forecast 2021-2026 ($ million) Exhibit 52: Chart on APAC - Year-over-year growth 2021-2026 (%) Exhibit 53: Data Table on APAC - Year-over-year growth 2021-2026 (%) 7.6 Rest of World (ROW) - Market size and forecast 2021-2026 Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) 7.7 US - Market size and forecast 2021-2026 Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million) Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million) Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%) Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%) 7.8 Canada - Market size and forecast 2021-2026 Exhibit 62: Chart on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 63: Data Table on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 64: Chart on Canada - Year-over-year growth 2021-2026 (%) Exhibit 65: Data Table on Canada - Year-over-year growth 2021-2026 (%) 7.9 Japan - Market size and forecast 2021-2026 Exhibit 66: Chart on Japan - Market size and forecast 2021-2026 ($ million) Exhibit 67: Data Table on Japan - Market size and forecast 2021-2026 ($ million) Exhibit 68: Chart on Japan - Year-over-year growth 2021-2026 (%) Exhibit 69: Data Table on Japan - Year-over-year growth 2021-2026 (%) 7.10 UK - Market size and forecast 2021-2026 Exhibit 70: Chart on UK - Market size and forecast 2021-2026 ($ million) Exhibit 71: Data Table on UK - Market size and forecast 2021-2026 ($ million) Exhibit 72: Chart on UK - Year-over-year growth 2021-2026 (%) Exhibit 73: Data Table on UK - Year-over-year growth 2021-2026 (%) 7.11 Germany - Market size and forecast 2021-2026 Exhibit 74: Chart on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 75: Data Table on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 76: Chart on Germany - Year-over-year growth 2021-2026 (%) Exhibit 77: Data Table on Germany - Year-over-year growth 2021-2026 (%) 7.12 Mexico - Market size and forecast 2021-2026 Exhibit 78: Chart on Mexico - Market size and forecast 2021-2026 ($ million) Exhibit 79: Data Table on Mexico - Market size and forecast 2021-2026 ($ million) Exhibit 80: Chart on Mexico - Year-over-year growth 2021-2026 (%) Exhibit 81: Data Table on Mexico - Year-over-year growth 2021-2026 (%) 7.13 Market opportunity by geography Exhibit 82: Market opportunity by geography ($ million) 8 Drivers, Challenges, and Trends 8.1 Market drivers 8.2 Market challenges 8.3 Impact of drivers and challenges Exhibit 83: Impact of drivers and challenges in 2021 and 2026 8.4 Market trends 9 Vendor Landscape 9.1 Overview 9.2 Vendor landscape Exhibit 84: Overview on Criticality of inputs and Factors of differentiation 9.3 Landscape disruption Exhibit 85: Overview on factors of disruption 9.4 Industry risks Exhibit 86: Impact of key risks on business 10 Vendor Analysis 10.1 Vendors covered Exhibit 87: Vendors covered 10.2 Market positioning of vendors Exhibit 88: Matrix on vendor position and classification 10.3 AbbVie Inc. Exhibit 89: AbbVie Inc. - Overview Exhibit 90: AbbVie Inc. - Product / Service Exhibit 91: AbbVie Inc. - Key offerings 10.4 Aerie Pharmaceuticals Inc Exhibit 92: Aerie Pharmaceuticals Inc - Overview Exhibit 93: Aerie Pharmaceuticals Inc - Product / Service Exhibit 94: Aerie Pharmaceuticals Inc - Key offerings 10.5 Alcon Inc. Exhibit 95: Alcon Inc. - Overview Exhibit 96: Alcon Inc. - Business segments Exhibit 97: Alcon Inc. - Key offerings Exhibit 98: Alcon Inc. - Segment focus 10.6 Bausch Health Co Inc Exhibit 99: Bausch Health Co Inc - Overview Exhibit 100: Bausch Health Co Inc - Business segments Exhibit 101: Bausch Health Co Inc - Key news Exhibit 102: Bausch Health Co Inc - Key offerings Exhibit 103: Bausch Health Co Inc - Segment focus 10.7 Hikma Pharmaceuticals Plc Exhibit 104: Hikma Pharmaceuticals Plc - Overview Exhibit 105: Hikma Pharmaceuticals Plc - Business segments Exhibit 106: Hikma Pharmaceuticals Plc - Key offerings Exhibit 107: Hikma Pharmaceuticals Plc - Segment focus 10.8 Nicox SA Exhibit 108: Nicox SA - Overview Exhibit 109: Nicox SA - Product / Service Exhibit 110: Nicox SA - Key offerings 10.9 Novartis AG Exhibit 111: Novartis AG - Overview Exhibit 112: Novartis AG - Business segments Exhibit 113: Novartis AG - Key offerings Exhibit 114: Novartis AG - Segment focus 10.10 Otsuka Pharmaceutical Co. Ltd. Exhibit 115: Otsuka Pharmaceutical Co. Ltd. - Overview Exhibit 116: Otsuka Pharmaceutical Co. Ltd. - Product / Service Exhibit 117: Otsuka Pharmaceutical Co. Ltd. - Key offerings 10.11 Pfizer Inc. Exhibit 118: Pfizer Inc. - Overview Exhibit 119: Pfizer Inc. - Product / Service Exhibit 120: Pfizer Inc. - Key news Exhibit 121: Pfizer Inc. - Key offerings 10.12 Viatris Inc. Exhibit 122: Viatris Inc. - Overview Exhibit 123: Viatris Inc. - Business segments Exhibit 124: Viatris Inc. - Key offerings Exhibit 125: Viatris Inc. - Segment focus 11 Appendix 11.1 Scope of the report 11.2 Inclusions and exclusions checklist Exhibit 126: Inclusions checklist Exhibit 127: Exclusions checklist 11.3 Currency conversion rates for US$ Exhibit 128: Currency conversion rates for US$ 11.4 Research methodology Exhibit 129: Research methodology Exhibit 130: Validation techniques employed for market sizing Exhibit 131: Information sources 11.5 List of abbreviations Exhibit 132: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

Small molecular drug

100 Deals associated with Brimonidine Tartrate/Timolol Maleate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Brimonidine Tartrate/Timolol Maleate	S01ED51	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Glaucoma	Japan	Senju Pharmaceutical Co., Ltd.	20 Sep 2019
Glaucoma, Open-Angle	Australia	AbbVie Pty Ltd.	07 Jan 2005
Ocular Hypertension	Australia	AbbVie Pty Ltd.	07 Jan 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Aibeta Crossover Study (ARVO2023)	Not Applicable	-	110	0.1% brimonidine/0.5% timolol	(naahrehkvi) = xptkaksmlj zroblunyuy (mskskkbnfe )	Positive	23 Apr 2023
				1% dorzolamide/0.5% timolol	(naahrehkvi) = dvtqenoowb zroblunyuy (mskskkbnfe )
APAO2019	Not Applicable	-	-	Brimonidine tartrate 0.2% - Timolol maleate 0.5%	kcibulxtyn(zkjeymatny) = CNS and respiratory depression were observed in the 3 neonates within 2 hours of administration of brimonidine tartrate 0.2% â timolol maleate 0.5% eye drops wdlvdssmqi (ofvjivgzqi ) View more	-	06 Mar 2019
AAO2012	Not Applicable	Ocular Hypertension	-	Dorzolamide/Timolol	hikmaopexh(oqnbjxvppk) = ocdykmkdjf qucztptmmo (zdfxtzusdz, 7.3)	Negative	12 Nov 2012
				Brimonidine/Timolol	hikmaopexh(oqnbjxvppk) = dinpjmyzui qucztptmmo (zdfxtzusdz, 5.1)
NCT01170884 (CTgov)	Phase 4	Glaucoma	121	bimatoprost 0.03% ophthalmic solution+brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution (Combigan® + Lumigan®)	enzetjuxrv(bqmrobqfls) = tscnmechel htuvvsiilr (axdygsuhss, rxjfouxucj - vubecsvpsy) View more	-	12 Jan 2012
				bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops (Lumigan®)	enzetjuxrv(bqmrobqfls) = npiewtgzgy htuvvsiilr (axdygsuhss, pfsimugdkv - wyevwrgjlb) View more
ARVO2011	Not Applicable	-	-	Brimonidine 0.2% / Timolol 0.5%	(qtjqvsrypa) = ehhmmeykqx gpibusqtsw (iadytxhvax )	Positive	01 Apr 2011
				Dorzolamide 2% / Timolol 0.5%	(qtjqvsrypa) = mrvwwxqomf gpibusqtsw (iadytxhvax )
NCT00822055 \| NCT00822081 (Pubmed \| Curr Med Res Opin)	Phase 4	Glaucoma, Open-Angle \| Ocular Hypertension	180	brimonidine-timolol	czhdcqynqn(wgpyphdpoo) = Patients on brimonidine-timolol reported less burning tpacznbgwd (rsmjldyvhc ) View more	-	01 Jul 2009
				dorzolamide-timolol
ARVO2009	Not Applicable	Conjunctival Diseases	-	Dorzolamide hydrochloride/Timolol maleate	tqrekzttvl(pmpnezxwli) = puvlitacon kvzelztoco (fbmeotnqsd ) View more	Positive	01 Apr 2009
				Brimonidine tartrate/Timolol maleate	tqrekzttvl(pmpnezxwli) = izmmcfynmp kvzelztoco (fbmeotnqsd ) View more
ARVO2008	Not Applicable	-	-	Brimonidine 0.2%/Timolol 0.5%	(ycdxsmddye) = cnaoherxav vohgbgkwcs (knlhhqzbhw ) View more	Positive	01 May 2008
				Dorzolamide 2%/Timolol 0.5%	(ycdxsmddye) = bzzbtzvbkw vohgbgkwcs (knlhhqzbhw ) View more
AAO2007	Not Applicable	-	-	Combigan	(wwgwvwiqsp) = cczvapewgj xgvudliwsy (srludnbaof )	Positive	12 Nov 2007
				Cosopt	(wwgwvwiqsp) = wleslizedb xgvudliwsy (srludnbaof )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis